glp-1/gip receptor agonist GLP1-GIP co-agonists: a promising evolution in the treatment of type 2 diabetes | Acta Diabetologica Beyond GLP1: modulating multiple nutrient-stimulated

The US Food and Drug Administration approved metformin to treat Type 2 diabetes almost thirty years ago, but it's not officially considered a weight loss drug

Vinci, P

Dietary contribution is approximately 300 mg/day with a total pool size of 1200 mg in men and 600 mg in women [10, 11]

This process is postulated to be mediated by insulin-dependent phosphorylation of proteins that play a crucial role in vesicle translocation

Side effects Commonly reported side effects include: Nausea Constipation Diarrhea Vomiting Stomach (abdominal) pain Indigestion Headache Other potential side effects: Fatigue Belching Heartburn Bloating Hair loss Decreased appetite Gastroesophageal reflux disease Injection site reactions Most GI side effects are more common in the first few weeks and tend to ease as your body adjusts